Pharmaceutical compositions comprising peg-asparaginase for the treatment of hivinfections

Pharmaceutical compositions comprising PEG-asparaginase for the treatment of HIV infections

PHARMACEUTICAL COMPOSITIONS THAT INCLUDE PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS.

El uso de un compuesto de PEG-ASNasa junto con al menos un compuesto seleccionado del grupo que consiste en compuestos inhibidores de proteasa, compuestos inhibidores de reductasa de ribonucleótido y compuestos inhibidores de transcriptasa inversa de VIH, en el que dichos compuestos inhibidores de reductasa de ribonucleótido son seleccionados entre hidroxiurea (HU), BW-348U87, tiosemicarbazona de 3-aminopiridina-2-carboxaldehído (3- AP), Amidox (VF 236; NSC-343341; N, 3, 4- trihidroxibencencarboximidamida), BILD 1257 (2-bencil-3- fenilpropionil-L-(N-metil)valil-L-3-(metil)valil-L-(N4, N4- tetrametilen) asparaginil-L-(3, 3-tetrametilen) aspartil-L- (4-metil)leucina), BILD 1357 (1-[1(R)-etil-2, 2- dimetilpropilamida] de ácido 2-bencil-3-fenilpropionil-L-(N- metil)valil-L-3-(metil)valil-L-(N4, N4- tetrametilen)asparaginil-L-(3, 3-tetrametilen)aspártico), BILD 1633, BILD 733 (3-fenilpropionil-L-(N-metil)valil-L-(3- metil)valil-L- [3-(pirrolidin-1- ilcaronil)]alanil-L- (1- carboxiciclopentil)glicil-L-(4-metil) leucinol, BILD 1263 (2-bencil-3-fenilpropionil-L-(N-metil)valil-L-3- (metil)valil-L-(N4, N4-tetrametilen)asparaginil-L-(3, 3- tetrametilen)aspartil-L-(4-metil)leucinol), BILD 1351 (ácido 1-[1(S)- [5(S)- [3-[todo-cis) -2, 6- dimetilciclohexil] ureido]- 2(S)-(3, 3-dimetil-2-oxobutil)- 6, 6-dimetil-4-oxoheptanoilamino]-1-[1(R)-etil-2, 2- dimetilpropilcarbamol]metil] ciclopentanocarboxílico), Cl-F- araA (2-cloro-9-(2-desoxi-2-fluoro-beta-D-arabino furanosil) adenina, DDFC (2¿-desoxi-2¿, 2¿- difluorocitidina), Didox (VF 147; NSC 324360; N, 3, 4- trihidroxibenzamida), Eurd (3¿-Etiniluridina), GTI 2040, GTI 2501, IMHAG (1-isoquinolilmetano-N-hidroxi-N¿- aminoguanina), LY 207702 (2¿, 2¿-difluoro-2¿-desoxi ribofuranosil-2, 6-diaminopurina), LY 295501 (N-[[3, 4- diclorofenil)amino]carbonil]2, 3-dihidro-5- benzofuransulfonamida), MDL 101731 (FMdC; KW 2331; (2E)-2¿- desoxi-2¿-(fluorometilencitidina), Parabactin Sulofenur (LY 186641; N-[[(4-clorofenil) amino]carbonil]-2, 3- ...

Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections

Method of inhibiting or treating Human Immunodeficiency Virus (HIV) infection, comprising administering to a patient in need thereof an effective amount of a pharmaceutically acceptable composition comprising a PEG-ASNase compound and optionally at least one compound selected from the group consisting of protease inhibitor compounds, ribonucleotide reductase inhibitor compounds and HIV reverse transcriptase inhibitor compounds.

Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen